These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26641242)

  • 21. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
    Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.
    van Milligen de Wit AW; van Deventer SJ; Tytgat GN
    Am J Gastroenterol; 1995 Jun; 90(6):893-900. PubMed ID: 7771416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
    Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
    Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical and endoscopic therapy of primary sclerosing cholangitis.
    Weismüller TJ; Lankisch TO
    Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):741-52. PubMed ID: 22117639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary sclerosing cholangitis in pregnancy refractory to ursodeoxycholic acid treatment: a case report.
    Leftwich H; Fang YM; Borgida A; Crombleholme W
    J Reprod Med; 2010; 55(11-12):517-9. PubMed ID: 21291041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
    J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Semin Gastrointest Dis; 2001 Apr; 12(2):103-12. PubMed ID: 11352117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment.
    Trauner M; Halilbasic E; Baghdasaryan A; Moustafa T; Krones E; Fickert P; Hofer H; Penner E
    Dig Dis; 2012; 30 Suppl 1():39-47. PubMed ID: 23075867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective single-center review of primary sclerosing cholangitis in children.
    Miloh T; Arnon R; Shneider B; Suchy F; Kerkar N
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):239-45. PubMed ID: 19121649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary sclerosing cholangitis.
    Stiehl A; Benz C; Sauer P
    Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
    van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The medical management of primary sclerosing cholangitis.
    Cullen SN; Chapman RW
    Semin Liver Dis; 2006 Feb; 26(1):52-61. PubMed ID: 16496233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent insights in primary sclerosing cholangitis.
    Ponsioen CY
    J Dig Dis; 2012 Jul; 13(7):337-41. PubMed ID: 22713082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
    Sabino J; Vieira-Silva S; Machiels K; Joossens M; Falony G; Ballet V; Ferrante M; Van Assche G; Van der Merwe S; Vermeire S; Raes J
    Gut; 2016 Oct; 65(10):1681-9. PubMed ID: 27207975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Oct; 13(19):. PubMed ID: 39404413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.